ArticleParasitology2025
From clinical research to public health action: addressing chronic female genital schistosomiasis in non-endemic countries.
Article in Parasitology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Female genital schistosomiasis (FGS) in migrants - a systematic review of reported cases.BMC women's health · 2026Pooled it
- Hospitalizations for schistosomiasis in Spain by sex: a population-based study using the national hospital discharge database (2016-2023).BMC infectious diseases · 2026Observational
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We analysed the early results of a screening and management protocol of imported female genital schistosomiasis (FGS) among migrant women from endemic countries. In total we screened 136 women, from which 39 had suspicion of FGS (serology-positive test and clinical signs and symptoms compatible). Median age was of 42.7 years [interquartile range (IQR 35-45)], median time living in the Europe (EU) was of 14 years (IQR 10-19) and all of them were coming from a West African country, mainly Senegal (17 out of 39; 43.6%). All of them had 1 or more clinical genitourinary findings [median 5 (IQR 2-6)], being the most prevalent pelvic pain, vaginal discharge and menstrual disorders. According to the protocol, colposcopy and cytology examination was performed in 11 participants, from whom 7 had findings compatible with FGS and 5 had low-grade cervical dysplasia with human papillomavirus (HPV)-negative results. After specific treatment with praziquantel (PZQ), we observed a high rate of resolution of clinical signs and symptoms, serology clearance at the 12th month of follow-up. Colposcopy lesions of 3 women assessed at the end of follow-up were fully resolved. Our findings and previous research support the implementation of management protocols of FGS in non-endemic countries, in spite of the knowledge gaps that still remain. Clinical trials need further assessment to determine the efficacy of PZQ, new diagnostic tools and the interaction between FGS, HPV and cervical cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.